HTT and Huntington disease: To this end, a recently released drug trial using the antisense oligonucleotide, IONIS-HTTR that targets Huntingtin mRNA and suppresses mutant HTT production, has shown promise as a potential disease-modifying HD therapy (Tabrizi et al., 2018).